查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1949603

臨床試驗市場－全球產業規模、佔有率、趨勢、機會及預測（按類型、階段、研究設計、適應症、最終用戶、地區和競爭格局分類，2021-2031年）

Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Type, By Phase, By Study Design, By Indication, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球臨床試驗市場預計將從 2025 年的 871.8 億美元成長到 2031 年的 1,302.5 億美元，複合年成長率為 6.92%。

這些試驗是對人體受試者進行的系統性研究，旨在評估新型藥物、外科手術或行為介入措施的安全性和有效性。市場成長的主要驅動力是慢性病（尤其是心血管疾病和癌症）盛行率的上升，這需要持續投資於藥物研發。此外，對個人化醫療日益成長的需求以及臨床試驗為收集不同人群數據而進行的策略性全球化也是推動行業擴張的關鍵因素。

市場概覽
預測期 2027-2031
市場規模：2025年 871.8億美元
市場規模：2031年 1302.5億美元
複合年成長率：2026-2031年 6.92%
成長最快的細分市場 藥物測試
最大的市場 亞太地區

儘管發展勢頭良好，但該行業在患者招募和留存方面仍面臨諸多挑戰，這往往會導致成本高昂的延誤和研究週期延長。此外，在地理分佈廣泛的地區管理大規模的受試者群體時，複雜的物流問題也進一步加劇了這些營運挑戰。為了因應這些限制，維持開發平臺所需的規模之大令人震驚。臨床研究組織協會 (ACRO) 的報告顯示，2024 年，其成員公司管理或參與了 8,854 項研究，涉及約 170 萬名患者，這表明應對這些物流挑戰需要付出巨大的營運努力。

市場促進因素

受現代藥物發現的複雜性和對新型生物製藥的追求所驅動，不斷成長的醫藥研發支出成為市場成長的關鍵因素。各大製藥公司持續投入數十億美元用於臨床項目，以滿足嚴格的監管標準並加速突破性治療方法的研發。例如，羅氏2024年年度報告顯示，其核心研發投資在2024年達到130.4億瑞士法郎，展現了其在經濟挑戰下對創新的堅定承諾。這筆巨額資金支持全球的多元化研究，特定區域成為重要的研究中心。世界衛生組織（世衛組織）記錄顯示，2024年西太平洋地區開展了27172項臨床試驗，凸顯了這些投資所支持的研究的廣泛地域範圍和龐大規模。

同時，人工智慧 (AI) 和先進分析技術的應用正在變革臨床試驗的運作方式，有效解決了資料管理和病患招募的關鍵低效問題。機器學習演算法等工具使申辦方能夠透過電子健康記錄更準確地識別合格的受試者，從而有效降低入組和保留率方面的高失敗率。這些數位化創新也支援即時監測和預測建模，最佳化試驗設計，並確保更嚴格遵守通訊協定。根據 eClinical Solutions 於 2024 年 1 月發布的《2024 年產業展望》，53% 的受訪產業領袖認為人工智慧和機器學習是最有可能提高試驗結果和效率的技術，這表明研究方法正明顯轉向技術主導。

市場挑戰

提高病患招募和留存率的持續困難是全球臨床試驗市場營運和財務成長的一大障礙。當研究中心無法在計畫時間內完成入組目標時，直接導致研究週期延長，進而造成成本大幅增加。這種營運上的挫折迫使申辦方將更多資源投入研究中心營運和資料系統維護中，而非推動開發平臺。隨著研究週期的延長，最終醫療產品的專利獨佔期縮短，顯著削弱了潛在的投資回報，並抑制了對未來高風險專案的資金配置。

這一瓶頸普遍存在，並且深深植根於當前的營運環境。根據臨床研究專業人員協會 (ACRP) 2024 年的數據，36% 的臨床研究機構將「受試者招募和留存」列為一項主要的營運挑戰。如此高的招募障礙發生率表明，儘管各方都在努力推進全球化策略，但吸引和留住受試者仍然是一個重要的摩擦點。這些延誤不僅會擾亂特定研究的進度，還會降低市場參與企業的整體成功率，直接阻礙整個全球產業的效率和成長。

市場趨勢

隨著越來越多的贊助商將複雜癌症和罕見遺傳疾病的根治性療法列為優先事項，細胞和基因療法臨床試驗的日益受到重視標誌著該領域結構發生了重大轉變。這種策略轉變需要專門的生產和臨床物流來滿足自體和異體療法的獨特需求，這使其有別於傳統的小分子藥物研發。儘管市場波動，但近期對高回報研發項目的持續需求表明了該領域的韌性。再生醫學聯盟 (ARM) 在 2025 年 1 月的「產業趨勢簡報」中強調了對這些先進治療方法的持續投入，並指出細胞和基因治療領域的投資活動成長了 30%，正在進行的全球臨床試驗數量增加了 3%。

同時，分散式和混合式臨床試驗模式的廣泛應用正在革新資料收集方式，將評估直接從研究中心轉移到患者家中。透過整合直接面向病患的供應鏈和遠端監測技術，申辦者有效地降低了參與門檻，克服了以往阻礙病患入組的地理限制。這種運作上的靈活性不僅加快了研究進程，還透過吸引遠離學術醫療中心的社區參與，顯著提高了研究人群的多樣性。為了佐證這種方法的有效性，塔夫茨藥物研發研究中心 (CSDD) 在 2025 年 1 月發布的「PACT 聯盟分析」報告中指出，與傳統的醫療機構為基礎的研究相比，分散式模式使美國印第安人或阿拉斯加原住民的參與率提高了近四倍。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球臨床試驗市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 按類型（藥物檢測、醫療設備檢測）
    • 依階段（第一階段、第二階段、第三階段、第四階段）
    • 依研究設計（介入性研究、觀察性研究、擴大參與研究）
    • 依適應症（自體免疫/發炎性疾病、腫瘤、中樞神經系統疾病、糖尿病、心血管疾病、其他疾病）
    • 按最終使用者（臨床研究機構、製藥和生物技術公司、臨床試驗機構等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美臨床試驗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲臨床試驗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太臨床試驗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲臨床試驗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美臨床試驗市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球臨床試驗市場：SWOT分析

第14章 波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • IQVIA
  • PPD
  • ICON
  • Labcorp
  • Charles River
  • Syneos Health
  • Parexel
  • Wuxi AppTec
  • SGS
  • Thermo Fisher Scientific

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 5082

The Global Clinical Trials Market is projected to expand from USD 87.18 Billion in 2025 to USD 130.25 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 6.92%. These trials represent systematic investigations involving human subjects designed to evaluate the safety and effectiveness of novel medical, surgical, or behavioral interventions. The market's growth is fundamentally propelled by the rising prevalence of chronic conditions, particularly cardiovascular diseases and cancer, which necessitates continuous funding for pharmaceutical research and development. Additionally, the growing demand for personalized medicine and the strategic globalization of clinical studies to capture diverse population data act as significant drivers for industry expansion.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 87.18 Billion
Market Size 2031USD 130.25 Billion
CAGR 2026-20316.92%
Fastest Growing SegmentPharmaceutical Trials
Largest MarketAsia Pacific

Despite this growth trajectory, the industry faces considerable obstacles related to patient recruitment and retention, issues that frequently result in expensive delays and prolonged study timelines. The logistical intricacies involved in managing large participant pools across geographically dispersed locations further complicate these operational hurdles. Highlighting the immense scale required to sustain development pipelines despite these constraints, the Association of Clinical Research Organizations (ACRO) reported that in 2024, its member companies managed or participated in 8,854 studies involving approximately 1.7 million patients, illustrating the massive operational effort needed to navigate these logistical challenges.

Market Driver

Rising pharmaceutical research and development (R&D) spending serves as a primary engine for market growth, driven by the intricacies of modern drug discovery and the quest for new biologics. Major pharmaceutical corporations continue to invest billions into clinical programs to meet strict regulatory standards and speed up the delivery of breakthrough treatments. For example, Roche's 'Annual Report 2024' noted that core R&D investments hit CHF 13.04 billion in 2024, demonstrating a steadfast dedication to innovation amidst economic challenges. This substantial financial backing fuels a wide range of global studies, with specific regions becoming key hubs; the World Health Organization (WHO) recorded 27,172 clinical trials in the Western Pacific region in 2024, highlighting the vast geographical scope and volume of research supported by these investments.

Concurrently, the adoption of artificial intelligence (AI) and advanced analytics is transforming clinical trial operations by resolving major inefficiencies in data management and patient recruitment. Tools like machine learning algorithms allow sponsors to better pinpoint eligible participants via electronic health records, effectively lowering the high failure rates linked to enrollment and retention. These digital innovations also enable real-time monitoring and predictive modeling, which optimize trial designs and ensure stricter protocol adherence. According to the '2024 Industry Outlook' by eClinical Solutions in January 2024, 53% of industry leaders surveyed named artificial intelligence and machine learning as the technologies most likely to improve outcomes and efficiency, marking a clear transition toward technology-driven research methods.

Market Challenge

The ongoing difficulty in successfully recruiting and retaining patients serves as a significant barrier to the operational and financial growth of the Global Clinical Trials Market. When research sites fail to achieve enrollment goals within the scheduled timeframe, the direct result is a costly prolongation of the study. This operational stall compels sponsors to direct extra funds solely toward maintaining site operations and data systems instead of progressing the development pipeline. As timelines extend, the effective period of patent exclusivity for the final medical product diminishes, severely cutting the potential return on investment and deterring capital allocation for future high-risk endeavors.

This bottleneck is extensive and deeply rooted in the current operational landscape. Data from the Association of Clinical Research Professionals (ACRP) in 2024 reveals that 36% of clinical research sites cited recruitment and retention as their primary operational challenge. Such a high incidence of enrollment hurdles suggests that, despite strategic efforts toward globalization, the inability to secure and keep participants remains a crucial point of friction. These delays do not merely disrupt specific study schedules but also collectively lower the rate of successful market entries, thereby directly impeding the overall efficiency and growth of the global sector.

Market Trends

The growing emphasis on Cell and Gene Therapy Clinical Studies marks a significant structural evolution as sponsors prioritize curative interventions for complex cancers and rare genetic conditions. This strategic shift demands specialized manufacturing and clinical logistics to manage the distinct needs of autologous and allogeneic therapies, setting them apart from conventional small molecule research. The sector's resilience is demonstrated by recent metrics showing a persistent demand for high-reward development programs despite market volatility; the Alliance for Regenerative Medicine (ARM) noted in its January 2025 'State of the Industry Briefing' that the cell and gene therapy sector saw a 30% rise in investment activity and a 3% increase in active global clinical trials, highlighting a lasting commitment to these advanced modalities.

At the same time, the widespread implementation of Decentralized and Hybrid Clinical Trial Models is revolutionizing data collection by shifting assessments from investigator sites directly to patients' homes. By incorporating direct-to-patient supply chains and remote monitoring technologies, sponsors are effectively lowering participation barriers and overcoming geographic limitations that previously hindered enrollment. This operational adaptability not only speeds up study timelines but also vastly improves the diversity of research populations by engaging communities far from academic medical centers. Validating this approach, the Tufts Center for the Study of Drug Development (CSDD) reported in its January 2025 'PACT Consortium Analysis' that decentralized models achieved a nearly fourfold increase in American Indian or Alaska Native participation compared to traditional site-based studies.

Key Market Players

  • IQVIA
  • PPD
  • ICON
  • Labcorp
  • Charles River
  • Syneos Health
  • Parexel
  • Wuxi AppTec
  • SGS
  • Thermo Fisher Scientific

Report Scope

In this report, the Global Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Trials Market, By Type

  • Pharmaceutical Trials
  • Medical Device Trials

Clinical Trials Market, By Phase

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Clinical Trials Market, By Study Design

  • Interventional
  • Observational
  • Expanded Access

Clinical Trials Market, By Indication

  • Autoimmune/Inflammation
  • Oncology
  • CNS
  • Diabetes
  • Cardiovascular
  • Others

Clinical Trials Market, By End User

  • Clinical Research Organizations
  • Pharmaceutical and Biotechnological Companies
  • Clinical Testing Laboratories
  • Others

Clinical Trials Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Trials Market.

Available Customizations:

Global Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Type (Pharmaceutical Trials, Medical Device Trials)
    • 5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
    • 5.2.3. By Study Design (Interventional, Observational, Expanded Access)
    • 5.2.4. By Indication (Autoimmune/Inflammation, Oncology, CNS, Diabetes, Cardiovascular, Others)
    • 5.2.5. By End User (Clinical Research Organizations, Pharmaceutical and Biotechnological Companies, Clinical Testing Laboratories, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Type
    • 6.2.2. By Phase
    • 6.2.3. By Study Design
    • 6.2.4. By Indication
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Type
        • 6.3.1.2.2. By Phase
        • 6.3.1.2.3. By Study Design
        • 6.3.1.2.4. By Indication
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Type
        • 6.3.2.2.2. By Phase
        • 6.3.2.2.3. By Study Design
        • 6.3.2.2.4. By Indication
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Type
        • 6.3.3.2.2. By Phase
        • 6.3.3.2.3. By Study Design
        • 6.3.3.2.4. By Indication
        • 6.3.3.2.5. By End User

7. Europe Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Type
    • 7.2.2. By Phase
    • 7.2.3. By Study Design
    • 7.2.4. By Indication
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Type
        • 7.3.1.2.2. By Phase
        • 7.3.1.2.3. By Study Design
        • 7.3.1.2.4. By Indication
        • 7.3.1.2.5. By End User
    • 7.3.2. France Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Type
        • 7.3.2.2.2. By Phase
        • 7.3.2.2.3. By Study Design
        • 7.3.2.2.4. By Indication
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Type
        • 7.3.3.2.2. By Phase
        • 7.3.3.2.3. By Study Design
        • 7.3.3.2.4. By Indication
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Clinical Trials Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Type
        • 7.3.4.2.2. By Phase
        • 7.3.4.2.3. By Study Design
        • 7.3.4.2.4. By Indication
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Clinical Trials Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Type
        • 7.3.5.2.2. By Phase
        • 7.3.5.2.3. By Study Design
        • 7.3.5.2.4. By Indication
        • 7.3.5.2.5. By End User

8. Asia Pacific Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Type
    • 8.2.2. By Phase
    • 8.2.3. By Study Design
    • 8.2.4. By Indication
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Type
        • 8.3.1.2.2. By Phase
        • 8.3.1.2.3. By Study Design
        • 8.3.1.2.4. By Indication
        • 8.3.1.2.5. By End User
    • 8.3.2. India Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Type
        • 8.3.2.2.2. By Phase
        • 8.3.2.2.3. By Study Design
        • 8.3.2.2.4. By Indication
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Type
        • 8.3.3.2.2. By Phase
        • 8.3.3.2.3. By Study Design
        • 8.3.3.2.4. By Indication
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Clinical Trials Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Type
        • 8.3.4.2.2. By Phase
        • 8.3.4.2.3. By Study Design
        • 8.3.4.2.4. By Indication
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Clinical Trials Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Type
        • 8.3.5.2.2. By Phase
        • 8.3.5.2.3. By Study Design
        • 8.3.5.2.4. By Indication
        • 8.3.5.2.5. By End User

9. Middle East & Africa Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Type
    • 9.2.2. By Phase
    • 9.2.3. By Study Design
    • 9.2.4. By Indication
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Type
        • 9.3.1.2.2. By Phase
        • 9.3.1.2.3. By Study Design
        • 9.3.1.2.4. By Indication
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Type
        • 9.3.2.2.2. By Phase
        • 9.3.2.2.3. By Study Design
        • 9.3.2.2.4. By Indication
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Type
        • 9.3.3.2.2. By Phase
        • 9.3.3.2.3. By Study Design
        • 9.3.3.2.4. By Indication
        • 9.3.3.2.5. By End User

10. South America Clinical Trials Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Type
    • 10.2.2. By Phase
    • 10.2.3. By Study Design
    • 10.2.4. By Indication
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Clinical Trials Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Type
        • 10.3.1.2.2. By Phase
        • 10.3.1.2.3. By Study Design
        • 10.3.1.2.4. By Indication
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Clinical Trials Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Type
        • 10.3.2.2.2. By Phase
        • 10.3.2.2.3. By Study Design
        • 10.3.2.2.4. By Indication
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Clinical Trials Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Type
        • 10.3.3.2.2. By Phase
        • 10.3.3.2.3. By Study Design
        • 10.3.3.2.4. By Indication
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. IQVIA
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. PPD
  • 15.3. ICON
  • 15.4. Labcorp
  • 15.5. Charles River
  • 15.6. Syneos Health
  • 15.7. Parexel
  • 15.8. Wuxi AppTec
  • 15.9. SGS
  • 15.10. Thermo Fisher Scientific

16. Strategic Recommendations

17. About Us & Disclaimer